Category Archives: Inside BIO Industry Analysis
2015 was a blockbuster year for FDA approvals of novel new medicines, many of them for serious and life-threatening conditions. As Dr. John Jenkins of the FDA’s Center for Drug Evaluation and Research (CDER) notes in a recent blog post, “During this past year, we approved many new drugs to treat various forms of cancer, including four to treat multiple myeloma, and others to treat lung, skin, breast, brain, colorectal, and other cancers. We also Read More >
Interstitial Cystitis: Understanding What It Is, and the Interstitial Cystitis Association’s Role in an IC Patient’s Life
If you mention Interstitial Cystitis (IC) to most people, including physicians, the majority of people have no idea what you are talking about. This is alarming because IC affects between 4-12 million people, just in the U.S. alone. The majority of IC patients are women, but both men and children can receive the diagnosis as well. So what is IC and how do you know if you have it? Interstitial cystitis (in-ter-stish-uhl sĭ-stī’tĭs), or as Read More >
Liquid biopsy is considered “liquid gold”. Estimates the global testing market to reach $20 billion by 2020.
Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation and the search for new cures and therapies for previously untreatable diseases. That’s why it is important that policy proposals designed to respond to the activities of outliers like Turing Pharmaceuticals and Valeant do not hurt America’s leadership in biotechnology innovation and investment. Read More >
The 2015 BIO Investor Forum is just two weeks away, and it’s gearing up to be the most productive Forum yet. The event will take place October 20-21, 2015 at the Parc 55 Hotel in San Francisco, California, and will feature several new programs and activities for attendees. Register now to join your colleagues for an exciting two days of networking, company presentations, BIO One-on-OneTM partnering meetings, and exciting expert-led panels. Here’s what to expect Read More >